Company Description
Organogenesis Holdings Inc., a regenerative medicine company, develops, manufactures, and commercializes solutions for the advanced wound care, and surgical and sports medicine markets in the United States.
The company’s advanced wound care products include Affinity, an amniotic membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Novachor, a chorion membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Apligraf, a bioengineered living cell therapy that produce spectrum of cytokines and growth factors; Dermagraft, a bioengineered product that produces human collagen, ECM, proteins, cytokines, and growth factors; NuShield, dehydrated placental tissue covering amnion and chorion membranes for spongy/intermediate layer intact; and PuraPly AM, an antimicrobial barrier that enables conformability and fluid drainage.
Its products also include FortiShield, a biosynthetic wound matrix for use as a temporary protective covering; PuraPly MZ, a micronized particulate version of PuraPly for the management of open wounds in the surgical setting; and CYGNUS Dual, a dehydrated placental tissue preserved to retain the ECM scaffold.
The company’s pipeline products include ReNu, a cryopreserved suspension used to support healing of soft tissues; PuraForce, a bioengineered porcine collagen surgical matrix for use in soft tissue reinforcement applications; and TransCyte, a bioengineered tissue for the treatment of partial thickness burns.
It serves hospitals, wound care centers, government facilities, ambulatory service centers, and physician office through direct sales representives and independent agencies.
Organogenesis Holdings Inc. was founded in 1985 and is headquartered in Canton, Massachusetts.
| Country | United States |
| Founded | 1985 |
| Industry | Drug Manufacturers - Specialty & Generic |
| Sector | Healthcare |
| Employees | 862 |
| CEO | Gary Gillheeney |
Contact Details
Address: 85 Dan Road Canton, Massachusetts 02021 United States | |
| Phone | 781 575 0775 |
| Website | organogenesis.com |
Stock Details
| Ticker Symbol | ORGO |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001661181 |
| CUSIP Number | 68621F102 |
| ISIN Number | US68621F1021 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Gary S. Gillheeney Sr. | President, Chief Executive Officer, Chair of the Board |
| David C. Francisco | Chief Financial Officer |
| Patrick Bilbo | Chief Operating Officer |
| Lori H. Freedman B.A., Esq., J.D. | Chief Administrative and Legal Officer |
| Brian Grow | Chief Commercial Officer |
| William R. Kolb CPA | Secretary |
| Robert Cavorsi | Vice President of Strategy |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Nov 19, 2024 | SC 13D | General statement of acquisition of beneficial ownership |
| Nov 14, 2024 | SC 13D/A | [Amend] General statement of acquisition of beneficial ownership |
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Nov 13, 2024 | 8-K | Current Report |
| Nov 12, 2024 | 10-Q | Quarterly Report |
| Nov 12, 2024 | 8-K | Current Report |
| Aug 15, 2024 | EFFECT | Notice of Effectiveness |
| Aug 13, 2024 | UPLOAD | Filing |
| Aug 8, 2024 | S-3 | Registration statement under Securities Act of 1933 |
| Aug 8, 2024 | 10-Q | Quarterly Report |